KLP Kapitalforvaltning AS Buys New Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

KLP Kapitalforvaltning AS purchased a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, Holdings Channel reports. The firm purchased 17,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,094,000.

A number of other institutional investors also recently made changes to their positions in JAZZ. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at $25,000. Jones Financial Companies Lllp grew its holdings in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares in the last quarter. UMB Bank n.a. increased its stake in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares during the last quarter. Lindbrook Capital LLC raised its holdings in shares of Jazz Pharmaceuticals by 82.6% during the fourth quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 176 shares during the period. Finally, Itau Unibanco Holding S.A. raised its holdings in shares of Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 over the last three months. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 3.4 %

Jazz Pharmaceuticals stock opened at $126.40 on Friday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The stock has a market cap of $7.68 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 1.04 and a beta of 0.44. The company’s 50-day moving average price is $132.27 and its two-hundred day moving average price is $122.32. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Analysts Set New Price Targets

JAZZ has been the subject of a number of recent research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. Barclays reissued an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.